Abstract
Introduction
Extensive studies revealed the involvement of both genetic and environmental factors in the pathogenesis of multiple sclerosis (MS). Environmental factors that have been suggested to promote the disease include climate, stress, viral infections, smoking, 1 childhood obesity, 2 low vitamin D concentrations, 1 or dietary habits. 3 The association between diet and the risk of developing MS or other inflammatory diseases was proposed already 50 years ago. 4 Since then, numerous studies investigated an association between MS risk and the consumption of foods and food components including milk, meat, fibers, proteins, fruits, vegetables, and fats. The majority of reports described a decreased MS risk with the consumption of low-calorie diets rich in fish, vegetables, and plant fibers. 5 In contrast, diets containing high amounts of dietary milk, meat, and animal fat correlated with an increasing MS prevalence. 5 Already in the 1950s, Swank et al. 6 observed that people who consume less animal fat as contained in a typical "Western Diet" had lower rates of MS. Coinciding with this, obesity as a result of high fat intake was later shown to negatively influence the disease, 2 especially during adolescence. However, more recent studies showed that the type of fatty acid, rather than avoiding fat intake at all, affects the disease. For instance, ω-3 polyunsaturated fatty acids were shown to induce a rather anti-inflammatory phenotype, whereas ω-6 polyunsaturated fatty acids were found to promote a pro-inflammatory environment. 7, 8 Fatty acids that are often discussed for their detrimental role in MS are saturated fatty acids. However, studies investigating saturated fats in the animal model of MS revealed harmful as well as beneficial effects depending on their aliphatic chain length. 9 already been linked to obesity, a long discussed risk factor in MS. Obesity is defined by the accumulation of white adipose tissue, an endocrine organ releasing proinflammatory factors such as leptin, tumor necrosis factor a (TNF-a), and interleukin-6 (IL-6). 10 These inflammatory signals may have a profound impact on CD4 + T-cell populations. Consequently, murine studies showed that diet-induced obesity can impact regulatory T cells (Treg) and particularly promote Th17 driven immunity. 11, 12 Obesity has been implicated in the exacerbation of inflammatory bowel disease (IBD), 13 collagen-induced arthritis, 14 and also models of MS. 15 Yet, a higher risk of developing MS has only been linked to obesity during young adulthood. 2 This observation emphasizes the need to further investigate single dietary factors of the "Western diet" that are associated with obesity, including animal-derived fats, rather than investigating obesity as such. One integral component of the "Western Diet" is saturated medium-and longchain fatty acids (LCFAs), such as lauric acid (LA) with an aliphatic tail of 12 carbon atoms. Lauric acid promotes the differentiation of murine and human CD4 + T cells toward Th1 and Th17 cells, producing the pro-inflammatory cytokines interferon-γ (IFN-γ) and IL-17A. The effect of lauric acid on Th17 cell polarization is directly mediated and did not occur through effects on dendritic cells (DCs). LCFAs also suppressed the differentiation of regulatory T cells (Treg) and decreased the expression of the anti-inflammatory cytokine IL-10. 9 Since it is now well accepted that the autoimmune basis of MS stems from an imbalance between pro-inflammatory Th1 and Th17 cells and anti-inflammatory Treg cells, LCFAs may be added to the list of risk factors affecting the disease. In fact, using experimental autoimmune encephalomyelitis (EAE) as a model of Th1 and/or Th17 cell-mediated disease, mice fed a diet rich in lauric acid displayed a more severe disease course than mice fed an otherwise completely matched control diet. This was mainly due to an increased frequency of Th17 cells in the spleen and the central nervous system (CNS) on day 10 day and 14 day post immunization, respectively. 9 Mechanistic studies revealed that the effect of LCFAs on T-cell differentiation is mediated by the activation of p38-MAPK signaling in CD4 + T cells. 9 LA treatment of T cells under Th17 cell polarizing conditions increased p38 phosphorylation, whereas Treg-cell differentiation correlated with decreased p38-MAPK activation. p38 is a well-known integrator of environmental stress and has been previously shown to not only be involved in T-cell differentiation 16 but also to be critical in models of MS. 17 Besides T cells, LCFAs further enhanced the phosphorylation of p38 in macrophages. 18 The addition of LCFAs to macrophages induced mRNA expression and secretion of TNF-α and IL-1β, which may contribute to increased Th17 responses in vivo. Considered together, LCFAs can alter the differentiation potential of T cells into proinflammatory T cells and promote macrophage responses in vitro. These studies suggest that increased concentrations of LCFAs in turn may contribute to excessive immune responses in MS.
Short-chain fatty acids in MS
For a long time, LCFAs were the focus of public and scientific considerations. It was only recently that short-chain fatty acids (SCFAs) came into the focus of scientific interest. Previously, SCFAs rather took a critical role in the public perception because of their usage in dietary products. Propionate (PA), an SCFA with a three carbon backbone, is a common environmental compound which is, for example, found in crustaceans. Moreover, PA was part of many preservatives used in the production of bread and pastries and thus was ingested by many people in their common diet at low concentrations. However, with new EU regulations, the usage of PA as food preservative declined. Interestingly, their decrease is paralleled by a recent increase in the incidence of several autoimmune diseases including MS.
Already some years ago, the potential positive effects of SCFAs in animals and humans have been discussed. A breakthrough, which gave a completely new view on the effect of SCFAs, was the discovery of their inhibitory effects on inflammatory processes.
In contrast to LCFAs, SCFAs with a three to five carbon atom backbone promote an anti-inflammatory environment by the induction of Treg. In addition, SCFAs were shown to suppress the production of proinflammatory Th17 cells, further corroborating their anti-inflammatory properties. Recent studies revealed that the administration of SCFAs into rodent inflammatory models inhibited the disease by increasing the number of Treg. 9, [19] [20] [21] For instance, in the animal model of MS, SCFAs ameliorate disease progression as a result of an increase in Treg cells and IL-10 production in the spleen and spinal cord. 9 An important mediator of SCFAs pivotal for the generation of Treg cells in vitro is lipin-2. The upregulation of lipin-2, paralleled by the overexpression of the JNK1 interacting protein JIP2, inhibits the activation of the JNK1 pathway, an activator of pro-inflammatory transcription factor NF-κB. 9 Lipin-2 has been shown previously to counteract the pro-inflammatory effects of saturated fatty acids on macrophages. 22 Indeed, additional effects of SCFAs on antigen-presenting cells, including macrophages and DCs, have recently been described for butyric acid, an SCFA with four carbon atoms. 23, 24 In vitro, bone-marrow-derived macrophages down-regulated lipopolysaccharide-induced pro-inflammatory mediators like nitric oxide, IL-6, and IL-12 upon treatment with SCFAs. 23 DCs treated with butyrate also showed reduced production of proinflammatory cytokines like IL-12p40 and IFN-γ. In contrast, DCs treated with butyrate released much higher amounts of the anti-inflammatory cytokine IL-10. 24 Other studies reported that butyrate increases the production of IL-23 by DCs, a cytokine important for the polarization of Th17 cells. 25 Others, however, reported that DCs treated with butyrate displayed a lower capacity of stimulating T cells. 24 It thus seems more likely that the beneficial effect of SCFAs reported in the disease model of MS, namely, the induction of Treg cells, is rather directly mediated by acting on T cells than via antigen-presenting cells.
Corroborating the in vitro findings, the administration of SCFAs during EAE induced Treg cells in the gut. 9 Indeed, the gut commensal bacteria are the main source of SCFAs, end products of bacterial fermentation of dietary fibers. The gut thus represents an anatomic site linking dietary fatty acids and the immune system.
Linking dietary fat intake to CNS autoimmunity-the gut microbiome
Many data on the immunopathology of MS stem from an animal model mimicking several aspects of the disease, EAE. 26 MS is an autoimmune disease of the CNS that is characterized by inflammatory processes at the blood-brain barrier with involvement of autoreactive macrophages, DCs, B lymphocytes, and T cells, leading to axonal damage and demyelination. EAE studies have revealed that potentially CNSspecific T cells are normal components of our immune system in a resting state. However, when activated, these cells migrate through secondary immune organs before they gain the capacity to cross the blood-brain barrier. Within the CNS, T cells get re-activated by local antigen-presenting cells that present the appropriate auto-antigen and thereby recruit other inflammatory cells leading to the destruction of myelin sheaths and consequently axon damage. It is well accepted that T cells are primed in the periphery before migrating to the CNS. This activation was shown to occur in the intestine, what is neither surprising nor unexpected given the fact that the intestinal tract harbors almost two-thirds of the body's immune cells. These cells do not stay stagnant in the gut but have the capacity to migrate to other parts of the body, including the CNS. 27 The intestine harbors trillions of microbial cells and thousands of different bacterial species known as the gut microbiota. A large amount of physiological functions, such as food digestion and competing with potential pathogens, have been described for the commensal gut bacteria. 28, 29 A vast collection of data argues for an essential role of the gut microbiota for the proper function of our immune system, metabolism, and brain function. It was demonstrated that distinct species of commensal bacteria have defined effects on immune functions. For instance, the segmented filamentous bacteria (SFB) support the differentiation of IL-17 producing lymphocytes. 30 In addition to disease-promoting bacteria, gut bacteria that potentially suppress inflammation have also been reported. Clostridia clusters XIVa and IV, as well as Bacteroides fragilis have been shown to suppress inflammatory conditions through the induction of Treg cells. 31 In general, changes in the microbial composition toward higher numbers of potentially pathogenic bacteria are leading to a dysbiotic gut microbiota, characterized by a dominance of Firmicutes over Bacteroidetes. 32 Dysbiosis in gut microbiota has been observed in several diseases such as IBD, 33 allergy, 21 and asthma. 34 While not expecting a direct correlation between the gut and brain autoimmunity, EAE studies indicate that the microbiota might play a role in MS as well. Using germ-free mice, Berer et al. 35 showed that the commensal gut bacteria are necessary for the induction of experimental autoimmunity. Consistently, oral antibiotic treatment significantly reduced bacterial populations in wild-type mice and thereby impaired the development of EAE. 36 Moreover, recently published studies in humans reported the presence of a dysbiotic gut microbiota in MS patients, characterized by a reduction in species belonging to Clostridia XIVa and IV clusters. 37 The composition of the intestinal microbiota is highly individual and influenced by numerous exogenous factors, including our diet. In the EAE model, an excess intake of dietary LCFAs modulated the gut microbiome and its metabolism. LCFAs decreased Prevotellaceae and Bacteroidetes families in the gut. In parallel, LCFA feeding resulted in increased amounts of LCFAs and decreased concentrations of SCFAs in the gut, paralleled by an increased frequency of Th17 cells in the small intestinal lamina propria. 9 It is thus intriguing that naive CD4 + T cells in the lamina propria are exposed to a Th17 cellenhancing microbiome, shifting the T-cell repertoire more toward a pro-inflammatory type. In contrast, the administration of PA increased the differentiation of Treg cells in the small intestine, thus leading to a more anti-inflammatory environment in the gut. 9 Indeed, most data discussing the mechanism for the effect of SCFAs demonstrate a pivotal involvement of Treg cells. In a murine model of IBD, the administration of SCFAs increased the level of Treg cells in the gut. 19 Additionally, the administration of butyrate to germ-free mice mimicked the effect of Clostridium colonization and increased Treg levels in colon lamina propria. 20 Naturally, SCFAs such as PA, acetate, and butyrate are generated by bacterial fermentation and are among the most abundant of these dietary metabolites with concentrations ranging from 50 to 100 mM. 38 In the gut, SCFAs were shown to act via signaling pathways such as activation of G proteincoupled receptors (GPCRs), inhibition of histone deacetylases (HDACs), and stimulation of histone acetyltransferase activity. 39 In summary, orally administered SCFAs promote the differentiation of Treg cells by directly acting on CD4 + T cells in the gut or by acting as HDAC inhibitors in the gut maintaining acetylation of genes important for Treg function.
Thus, SCFA, as naturally occurring nutrients 38 or fermentation products, may represent an attractive therapeutic option for autoimmune diseases like MS by potentially triggering the production of anti-inflammatory Treg cells. So far, influencing MS via direct effects on Treg cells, for example, via super-agonistic anti-CD28 antibodies, has been considered valuable but not practically feasible unless in specific experimental conditions. 40 In contrast, SCFAs are naturally occurring products with a low side-effect profile, rendering them attractive for future clinical trials in MS patients, for example, as add-on therapy to established immunotherapies or as background for dietary recommendations.
Conclusion
Data on saturated fatty acids and the gut extend our observations on the functional importance of the microbiome for immune reactions and functionally link dietary fat intake with microbiome changes, T-cell differentiation, and finally, the course of EAE/ MS. It seems possible that modifications of the gut microbiome and its metabolism represent interesting targets for the treatment of MS and potentially other autoimmune diseases. Such a goal may be achieved by intake of appropriate types of dietary fibers that have the ability to support the growth and proliferation of SCFA-producing bacteria, thus enabling the differentiation of naive CD4 + T cells into Treg cells rather than into pathogenic Th1 and Th17 cells. Furthermore, SCFAs are ingested as food preservatives in our daily diet, however, at quite low concentrations. SCFAs may thus be orally applied as food additive in our daily diet, likely resulting in therapeutically relevant amounts of SCFAs delivered to the distal portions of the intestinal tract.
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